Business Of Biotech BoB@JPM: Kasper Roet, Ph.D., QurAlis
10 snips
Mar 17, 2025 Kasper Roet, Ph.D., is the founder and CEO of QurAlis, a biotech innovator focused on genetic medicines for ALS. In this fascinating conversation, he discusses his journey from the Dutch Brain Bank to leading a consortium aimed at reforming the conservative FDA regulations that are driving clinical trials offshore. Roet emphasizes the critical need for a flexible approach to expedite therapy approvals and shares insights on the advancements in genetic medicine since the first ALS gene was discovered.
AI Snips
Chapters
Transcript
Episode notes
From IT to Biotech
- Kasper Roet started his career in IT during the internet boom, building computers and networks.
- His passion for biology led him back to school for medical biology and neuroscience, pursuing gene therapy.
Early Computers
- Roet's first computer was a Commodore 64, preceded by an Atari game console.
- He enjoyed taking them apart and trying to improve their performance for better gaming.
Dutch Brain Bank Experience
- Roet's experience at the Dutch Brain Bank provided hands-on experience with brain tissue and autopsies.
- This experience highlighted the frequent misdiagnosis of patients based on clinical symptoms alone.